Masoud H. Manjili
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Masoud H. Manjili is an Associate Professor at Virginia Commonwealth University School of Medicine in the United States. His research focuses on immunology, particularly in areas such as cancer immunotherapy, organ transplantation, and the role of the tumor microenvironment. Recent publications include works on theoretical models for interpreting immune phenomena and the adaptation model of immunity, contributing significantly to the field's understanding of immune responses and treatments.
Articles (17)
Chemotherapy-induced tumor dormancy is a major barrier to curative cancer therapy, particularly in triple-negative breast cancer (TNBC), where dormant residual cells evade treatment and fuel late relapses. To define survival mechanisms sustaining dormancy, we examined four breast cancer models: HER2-positive murine MMC and human SK-BR-3, and TNBC murine 4T1 and human MDA-MB-231. Dormancy was induced with low-dose FAC (5-Fluorouracil, Adriamycin, Cyclophosphamide). Across all models, dormant cells maintained high Bcl-xL expression. shRNA knockdown of Bcl-xL increased chemotherapy-induced apoptosis and prevented relapse in vitro and in vivo. Pharmacologic inhibition with A-1331852 improved chemotherapy, particularly in TNBC, and transient dosing avoided compensatory Survivin induction. Systemic A-1331852 suppressed relapse but caused off-target toxicity, whereas intratumoral delivery preserved efficacy and safety but failed to eliminate early lung dissemination, as confirmed by ex vivo culture of dormant tumor cells. Notably, disseminated cell frequency inversely correlated with primary tumor size during neoadjuvant chemotherapy, underscoring the need for systemic therapies targeting distant dormant cells. These findings identify Bcl-xL as a central survival factor in chemotherapy-induced dormancy, and suggest that tumor-targeted systemic delivery of A-1331852 may eradicate disseminated dormant cells and prevent metastatic relapse in high-risk TNBC.
Year:
2026
Immunology progresses not merely by accumulating data but by evolving the conceptual lenses through which those data are interpreted; yet for six decades the self–non‐self/infectious‐non‐self (SNS/INS) paradigm—casting allogeneity as activating signal and ‘self’ as intrinsically tolerogenic—has dominated research design, peer review and curriculum. This, in turn, systematically amplifies concordant findings while attenuating evidence for tissue integrity, metabolic, symbiotic and network‐centric cues. This conceptual monoculture appears as a hidden dogma that impedes breakthroughs in our understanding of the immune system and the development of curative therapies. By institutionalising theoretical immunology as a formal discipline and treating models as explicit, testable tools rather than hidden assumptions, immunologists can sharpen hypothesis generation and achieve a better understanding of existing data. This essay provides an overview of empirically grounded theoretical models to counter monoculture, clarify how frames shape interpretation, and expand the field's conceptual toolkit.
Year:
2025
The quest for a curative cancer immunotherapy remains elusive, hindered by a longstanding focus on tumor cell elimination through cytotoxic mechanisms. However, mounting evidence points to an underappreciated dimension of immune function: its capacity for tissue remodeling and homeostasis, which can shape a tumor-inhibitory microenvironment. This perspective review highlights the adaptation model of immunity, which reframes the immune response as a dual force capable of both preserving and disrupting tissue integrity. Central to this model is Signal IV, a novel pathway in which self-reactive immune cells interact with adaptation receptors (AdRs) on tissue cells through adaptation ligands (AdLs) on immune cells. This interaction activates anti-apoptotic pathways in target cells, enabling immune responses to promote tissue survival and homeostasis even in the presence of cytotoxic mediators. Crucially, the downregulation of AdRs in stromal cells, while preserved in malignant cells, creates a tumor-promoting microenvironment, whereas the reverse fosters tumor rejection. This paradigm challenges conventional approaches by shifting the focus from tumor cell destruction to restoring tissue integrity, offering a revolutionary framework for immunotherapy. By targeting the AdR–AdL axis to reprogram the tumor microenvironment, the adaptation model proposes a transformative strategy for harnessing immune responses to achieve durable cancer control.
Year:
2025
Traditional organ transplantation relies on the Self–Non‐self (SNS) model of immunity, focusing on donor–recipient compatibility and aggressive immunosuppression to prevent acute rejection. Although effective early, this strategy does not prevent chronic rejection and cannot account for operational tolerance, failure of perfectly HLA‐matched grafts, or the occasional spontaneous acceptance of a fully mismatched organ. The adaptation model of immunity offers a different lens. In the thymus, “central adaptation” programs T cells to recognise self‐peptide–MHC (pMHC) so they can later recognise different tissues to facilitate tissue repair and homeostasis. Whether a graft thrives or fails depends on how quickly this self‐oriented circuitry can operate. Autografts and isografts arrive with their own extracellular‐matrix (ECM) “memory”, and recipient T cells immediately recognise their pMHC, triggering tissue‐remodelling responses. Allografts must adapt to new ECM—a transition that is associated higher levels of graft injury allowing indirect antigen presentation. Until adaptation is complete, recipient T cells mount cytotoxic rather than reparative responses because of antigen cross‐presentation, during which the graft relies on donor‐derived tissue‐resident memory T cells (T RM ) to maintain integrity. Therapeutically, interventions that preserve or expand graft‐borne T RM , or that pharmacologically enhance adaptation‐receptor signalling, could hasten this donor‐to‐host reprogramming. By replacing blanket immunosuppression with targeted promotion of tissue‐remodelling immunity, the adaptation model charts a path toward long‐term graft survival without the lifelong risks of today's regimens.
Year:
2025
Background Metabolic dysfunction–associated fatty liver disease (MAFLD) can progress to hepatocellular carcinoma (HCC), yet the immune mechanisms driving this transition remain unclear. Methods In a chronic Western diet (WD) mouse model, we performed single‐nuclei RNA sequencing to track MAFLD progression into HCC and subsequent tumour inhibition upon dietary correction. Results Carcinogenesis begins during MAFLD, with tumour cells entering dormancy when HCC is mitigated. Rather than purely tolerogenic, the liver actively engages immune responses targeting myofibroblasts, fibroblasts and hepatocytes to maintain tissue homeostasis. Cytotoxic cells contribute to the turnover of liver cells but do not primarily target the tumour. NKT cells predominate under chronic WD, while monocytes join them in HCC progression on a WD. Upon dietary correction, monocyte‐driven immunity confers protection against HCC through targeting tissue homeostatic pathways and antioxidant mechanisms. Crucially, liver tissue response—not merely immune activation—dictates whether tumours grow or regress, emphasising the importance of restoring liver tissue integrity. Also, protection against HCC is linked to a distinct immunological pattern, differing from healthy controls, underscoring the need for immune reprogramming. Conclusion These findings reveal the dual roles of similar pathways, where immune patterns targeting different cells shape distinct outcomes. Restoring tissue homeostasis and regeneration creates a tumour‐hostile microenvironment, whereas tumour‐directed approaches fail to remodel the TME. This underscores the need for tissue remodelling strategies in cancer prevention and treatment.
Year:
2025
Year:
2025
Background/Objectives: Preclinical and clinical evidence supports a chaperone-based vaccination platform for cancer immunotherapy. The objective of this study is to interrogate the next generation of chaperone-based immune modulator, termed Flagrp170, which was constructed by fusing a defined NF-κB-activating microbial sequence with a large stress protein with a superior antigen-holding/presenting property in the setting of antigen-targeted cancer vaccination. Methods: Bone marrow-derived dendritic cells were treated with Flagrp170 protein or an unmodified parental chaperone molecule (i.e., Grp170), followed by an analysis of DC activation and DC-mediated T cell priming using both in vitro and in vivo models. Antitumor vaccine responses in mice receiving tumor antigens (e.g., gp100, Her2/neu) complexed with Flagrp170 or Grp170 were examined through multiple immune assays. The potential use of a Flagrp170-based chaperone vaccine to sensitize tumors to anti-PD-1 therapy was also evaluated. Results: Flagrp170 not only retains the intrinsic ability of the parent chaperone to facilitate antigen cross-presentation, but also acquires a unique capacity to stimulate DCs efficiently through the engagement of TLR5-NF-κB signaling. This chimeric chaperone shows superior activity compared to the unmodified parental molecule, resulting in enhanced DC activation and T cell priming. Vaccination with Flagrp170 complexed to tumor antigens induces a robust T cell response against primary tumors and metastases, a process critically dependent on CD8+ DCs. Additionally, the Flagrp170 chaperone vaccine can efficiently generate and expand tumor-reactive T cells. The consequent remodeling of the tumor microenvironment towards a Th1/Tc1 dominant immune phenotype significantly potentiates cancer responsiveness to anti-PD1 therapy. Conclusions: Given the safety and T cell stimulation profiles of the chaperone–antigen complex vaccine already established in our recent clinical trial, this new generation of chaperone cargo, capable of delivering both antigenic targets and pathogen-associated immunoactivating signals simultaneously, represents a promising strategy to potentially improve the low response rates in patients receiving immune checkpoint inhibitors.
Year:
2025
Our understanding of the immune response is far from complete, missing out on more detailed explanations that could be provided by molecular insights. To bridge this gap, we introduce the quantum model of T‐cell activation. This model suggests that the transfer of energy during protein phosphorylation within T cells is not a continuous flow but occurs in discrete bursts, or ‘quanta’, of phosphates. This quantized energy transfer is mediated by oscillating cycles of receptor phosphorylation and dephosphorylation, initiated by dynamic ‘catch‐slip’ pulses in the peptide‐major histocompatibility complex‐T‐cell receptor (pMHC‐TcR) interactions. T‐cell activation is predicated upon achieving a critical threshold of catch‐slip pulses at the pMHC‐TcR interface. Costimulation is relegated to a secondary role, becoming crucial only when the frequency of pMHC‐TcR catch‐slip pulses does not meet the necessary threshold for this quanta‐based energy transfer. Therefore, our model posits that it is the quantum nature of energy transfer—not the traditional signal I or signal II—that plays the decisive role in T‐cell activation. This paradigm shift highlights the importance of understanding T‐cell activation through a quantum lens, offering a potentially transformative perspective on immune response regulation.
Year:
2024
Background Metabolic dysfunction–associated fatty liver disease (MAFLD) can progress to hepatocellular carcinoma (HCC), yet the immune mechanisms driving this transition remain unclear. Methods In a chronic Western diet (WD) mouse model, we performed single-nuclei RNA sequencing to track MAFLD progression into HCC and subsequent tumor inhibition upon dietary correction. Results Carcinogenesis begins during MAFLD, with tumor cells entering dormancy when HCC is mitigated. Rather than purely tolerogenic, the liver actively engages immune responses targeting myofibroblasts, fibroblasts and hepatocytes to maintain tissue homeostasis. Cytotoxic cells contribute to turnover of liver cells but do not primarily target the tumor. NKT cells predominate under chronic WD, while monocytes join them in HCC progression on a WD. Upon dietary correction, monocyte-driven immunity confers protection against HCC through targeting tissue homeostatic pathways and antioxidant mechanisms. Crucially, liver tissue response—not merely immune activation—dictates whether tumors grow or regress, emphasizing the importance of restoring liver tissue integrity. Also, protection against HCC is linked to a distinct immunological pattern, differing from healthy controls, underscoring the need for immune reprogramming. Conclusion These findings reveal the dual roles of similar pathways, where immune patterns targeting different cells shape distinct outcomes. Restoring tissue homeostasis and regeneration creates a tumor-hostile microenvironment, whereas tumor-directed approaches fail to remodel the TME. This underscores the need for tissue remodeling strategies in cancer prevention and treatment. Lay summary Our study challenges the traditional view that the liver is purely tolerant to immune responses, revealing that it actively regulates immunity to maintain tissue health. We found that liver cancer (HCC) begins during fatty liver disease (MAFLD) but can be halted if immune cells—especially monocytes—restore tissue integrity. Instead of focusing solely on killing tumors, effective immunotherapy should harness the body’s natural ability to repair the liver, creating an environment where cancer cannot thrive. This discovery paves the way for innovative treatments that promote immune-driven tissue regeneration as a strategy for cancer prevention and therapy.
Year:
2024
The tumor microenvironment (TME) is a complex and dynamic ecosystem that includes a variety of immune cells mutually interacting with tumor cells, structural/stromal cells, and each other. The immune cells in the TME can have dual functions as pro-tumorigenic and anti-tumorigenic. To understand such paradoxical functions, the reductionistic approach classifies the immune cells into pro- and anti-tumor cells and suggests the therapeutic blockade of the pro-tumor and induction of the anti-tumor immune cells. This strategy has proven to be partially effective in prolonging patients’ survival only in a fraction of patients without offering a cancer cure. Recent advances in multi-omics allow taking systems immunology approach. This essay discusses how a systems immunology approach could revolutionize our understanding of the TME by suggesting that internetwork interactions of the immune cell types create distinct collective functions independent of the function of each cellular constituent. Such collective function can be understood by the discovery of the immunological patterns in the TME and may be modulated as a therapeutic means for immunotherapy of cancer.
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2020
Year:
2020
Collaborators (2)
Xiang-Yang Wang
University of Virginia School of Medicine
Arun Sanyal
Professor of Medicine
Virginia Commonwealth University
Make your next move.
Prepare your application
Review drafts before you send them.